Select the name of the type of clinical care program you would like more information about …

Example: ‘B’ for Bladder Cancer

Cancer Treatment A-Z

Skip to content. | Skip to navigation

Personal tools

Navigation

You are here: Home / News / 2011 News / Clinical Trial Shows Promise for Non-small Cell Lung Cancer

Clinical Trial Shows Promise for Non-small Cell Lung Cancer

by Susan Lucas last modified Apr 04, 2011 03:32 PM
Clinical Trial Shows Promise for Non-small Cell Lung Cancer

Mark Socinski, MD

CHAPEL HILL, N.C. - A clinical trial led by UNC Lineberger physician-researcher Mark Socinski, MD has shown that Abraxane® -- a chemotherapy agent previously used for metastatic breast cancer – is effective as a first-line treatment for patients with advanced non-small cell lung cancer.

The Phase 3 trial, which was conducted at UNC and 101 other sites globally, enrolled more than 1000 patients in the study – one of the largest clinical studies ever conducted for non-small cell lung    cancer.

"This is exciting news for lung cancer patients and has important implications not only in late stage cancer but also in earlier stages of the disease," Socinski said.

Read full news release on Abraxis BioScience websiteIcon indicating that a link will open an external site..